Investors

Recent News
Oct 4, 2022
Aridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority Study

On track to complete data compilation and analyses, with top-line data expected to be announced in December '22 LOS GATOS, Calif., Oct. 4, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc....

Sep 27, 2022
Aridis Pharmaceuticals Announces Withdrawal of Public Offering of Common Stock

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today...

Sep 26, 2022
Aridis Pharmaceuticals Announces Proposed Public Offering of Common Stock

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today...

OTCQBARDS
Stock Info
OTCQBARDS